Haplotype-based stratification of Huntington's disease by Chao, Michael J. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/102184/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Chao, Michael J., Gillis, Tammy, Atwal, Ranjit S., Srinidhi Mysore, Jayalakshmi, Arjomand,
Jamshid, Harold, Denise, Holmans, Peter Alan, Jones, Lesley, Orth, Michael, Myers, Richard H.,
Kwak, Seung, Wheeler, Vanessa C., MacDonald, Marcy E., Gusella, James F. and Lee, Jong-Min




Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 ͳ
Haplotype-based stratification of Huntington's disease ͳ ʹ 
Michael J. Chao1,2, Tammy Gillis1, Ranjit S. Atwal1,2, Jayalakshmi Srinidhi Mysore1, ͵ 
Jamshid Arjomand3, Denise Harold4,$,&, Peter Holmans4,$, Lesley Jones4,$, Michael Ͷ 
Orth5,$, Richard H. Myers6,$, Seung Kwak7,$, Vanessa C. Wheeler1,2,$, Marcy E. ͷ 
MacDonald1,2,8,$, James F. Gusella1,8,9,$, and Jong-Min Lee1,2,8,$,* ͸ ͹ 
1 Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts ͺ 
General Hospital, Boston, MA 02114, USA ͻ 
2 Department of Neurology, Harvard Medical School, Boston, MA 02115, USA ͳͲ 
3 Genea Biocells, San Diego, CA 92037, USA ͳͳ 
4 Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, ͳʹ 
Department of Psychological Medicine and Neurology, School of Medicine, Cardiff ͳ͵ 
University, Cardiff, United Kingdom ͳͶ 
5 Department of Neurology, University of Ulm, Germany ͳͷ 
6 Department of Neurology and Genome Science Institute, Boston University School of ͳ͸ 
Medicine, Boston, MA 02118, USA ͳ͹ 
7 CHDI Foundation, Princeton, NJ 08540, USA ͳͺ 
8 Medical and Population Genetics Program, the Broad Institute of M.I.T. and Harvard, ͳͻ 
Cambridge, MA 02142, USAʹͲ 
9 Department of Genetics, Harvard Medical School, Boston, MA 02115, USA ʹͳ 
$ Founding GeM-HD Consortium investigators ʹʹ 
& Present address: School of Biotechnology, Dublin City University, Dublin 9, Ireland ʹ͵ ʹͶ 
 ʹ
* Correspondence: Dr. JM Lee, Center for Human Genetic Research, Massachusetts ͳ 
General Hospital, 185 Cambridge Street, Boston, MA 02114, USA. Tel: 617-643-9714; ʹ 
Fax: 617-726-5735; e-mail: jlee51@mgh.harvard.edu ͵ Ͷ 
Running title: Haplotype of Huntington's diseaseͷ ͸ 
Keywords: Huntington's disease, haplotype, strafication, SNP͹ 
 ͵
ABSTRACT  ͳ ʹ 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused ͵ 
by expansion of a CAG trinucleotide repeat in HTT, resulting in an extended Ͷ 
polyglutamine tract in huntingtin. We and others have previously determined that the ͷ 
HD-causing expansion occurs on multiple different haplotype backbones, reflecting ͸ 
more than one ancestral origin of the same type of mutation. In view of the therapeutic ͹ 
potential of mutant allele-specific gene silencing, we have compared and integrated two ͺ 
major systems of HTT haplotype definition, combining data from 74 sequence variants ͻ 
to identify the most frequent disease-associated and control chromosome backbones ͳͲ 
and revealing that there is potential for additional resolution of HD haplotypes. We ͳͳ 
have used the large collection of 4,078 heterozygous HD subjects analyzed in our ͳʹ 
recent genome-wide association study of HD age at onset to estimate the frequency of ͳ͵ 
these haplotypes in European subjects, finding that common genetic variation at HTT ͳͶ 
can distinguish the normal and CAG-expanded chromosomes for more than 95% of ͳͷ 
European HD individuals. As a resource for the HD research community, we have also ͳ͸ 
determined the haplotypes present in a series of publicly available HD subject-derived ͳ͹ 
fibroblasts, induced pluripotent cells, and embryonic stem cells in order to facilitate ͳͺ 
efforts to develop inclusive methods of allele-specific HTT silencing applicable to most ͳͻ 
HD patients. Our data providing genetic guidance for therapeutic gene-based targeting ʹͲ 
will significantly contribute to the developments of rational treatments and ʹͳ 
implementation of precision medicine in HD. ʹʹ ʹ͵ 
 Ͷ
INTRODUCTION ͳ ʹ 
Huntington’s disease (HD) [MIM 143100] is a progressive neurodegenerative disorder ͵ 
caused by expansion of a CAG repeat in huntingtin (HTT) exon 1 that lengthens a Ͷ 
normally polymorphic polyglutamine tract in HTT 1 and produces characteristic motor ͷ 
disturbances, along with cognitive and psychiatric manifestations.2 Both the age at ͸ 
onset and the age at death of HD subjects are inversely correlated with the length of ͹ 
their CAG repeat, while the duration from onset to death, typically 15-20 years is ͺ 
largely independent of the mutation size.3,4 Currently, there is no treatment to either ͻ 
delay the onset or slow the progression of HD, but the recent discovery of genetic ͳͲ 
modifiers of age at onset establishes that the rate of HD pathogenesis can be altered ͳͳ 
before symptoms appear.5 Genetic analysis of large HD cohorts has demonstrated that ͳʹ 
HD is inherited as a complete dominant where a single mutant HTT allele determines ͳ͵ 
the timing of disease onset, with no discernible impact of either the normal HTT allele ͳͶ 
or, when present, a second mutant HTT allele.4 Consequently, suppression of the ͳͷ 
expression of mutant HTT is an appealing therapeutic strategy which, if achieved in an ͳ͸ 
allele-specific manner,6 could avoid any potential negative consequences attributable to ͳ͹ 
deficiency of normal huntingtin activity.  ͳͺ 
HTT allele-specific gene silencing strategies can either directly target the ͳͻ 
expanded CAG repeat or aim at other genetic variants in the surrounding haplotype.7-9ʹͲ 
While the former is an attractive target that would be applicable in all HD subjects, ʹͳ 
establishing allele specificity in individuals where the second HTT CAG repeat is high ʹʹ 
in the normal range, and limiting the effect to HTT when there are other expressed ʹ͵ 
CAG repeats in the human genome may be technically challenging. However, targeting ʹͶ 
 ͷ
genetic variants on the mutant HTT haplotype can achieve allele-specificity only in ͳ 
those HD individuals who are heterozygous for those variants.10-12 A multiplicity of ʹ 
HTT haplotypes, with normal and expanded repeats, have been observed in HD ͵ 
individuals of European ancestry.13-17 We have previously delineated the 8 most Ͷ 
common HTT haplotypes bearing expanded alleles based upon 21 genetic variants14,18ͷ 
while others have described 3 major haplogroups,16 which they recently resolved into ͸ 
subtypes using 63 variants.11 The two marker sets, which are only partially overlapping, ͹ 
have each been used to define sites that are most frequently heterozygous in HD ͺ 
subjects as potential targets for allele-specific HTT silencing.6,11 In order to facilitate ͻ 
research and development towards this goal, we have compared and integrated the two ͳͲ 
haplotype systems, better estimated HTT haplotype frequencies on normal and disease ͳͳ 
chromosomes in Europeans, and delineated the HTT haplotypes present in publicly ͳʹ 
available cell line resources available to the HD research community.  ͳ͵ ͳͶ 
MATERIALS AND METHODS ͳͷ ͳ͸ 
Definitions of HTT haplotypes ͳ͹ 
Selection of variants, mainly single-nucleotide polymorphisms (SNPs), and samples ͳͺ 
initially used to characterize HTT haplotypes on HD expanded chromosomes and ͳͻ 
normal chromosomes were described elsewhere.14 Briefly, twenty SNPs and one 3 bp ʹͲ 
insertion-deletion that showed significant association with HD in either 1) comparison ʹͳ 
of all HD vs. controls, or 2) comparison of those HD individuals lacking the major ʹʹ 
disease haplotype vs. controls, were used for haplotype phasing.14 The HTT CAG ʹ͵ 
repeat sizes in HD individuals were coded as bi-allelic genotypes (expanded and ʹͶ 
 ͸
normal), each person being a heterozygote. In contrast, each control individual was ͳ 
coded as homozygous normal for the HTT CAG repeat. Haplotype phasing of SNP ʹ 
genotypes was performed by the MaCH program,19 and the ten most frequent ͵ 
haplotypes on each of expanded chromosomes and normal chromosomes were Ͷ 
identified. As four haplotypes overlapped between both disease and normal, the union ͷ 
set comprised 16 distinct haplotypes. Definitions of haplotypes described previously ͸ 
(hap.01 ~ hap.07) 14 are same as those in this study. The phylogeny tree of haplotypes ͹ 
was obtained by the MEGA5 program (neighbor-joining method, P-distance model; ͺ 
http://www.megasoftware.net/).  ͻ ͳͲ 
Haplotype-specific SNP sites for mutant allele-selective silencing ͳͳ 
Previously, based on cumulative heterozygosity analyses of HD subjects with European ͳʹ 
ancestry, we revealed 20 SNP sites that can be targeted for mutatn allele-specific HTTͳ͵ 
silencing / lowering. 18 In order to relate alleles of target SNPs to haplotypes, we ͳͶ 
determined consensus alleles of those 20 SNPs (10 exon SNPs and 10 intron SNPs) for ͳͷ 
each haplotype. Briefly, for a given haplotype, we extracted chromosomes from 1000 ͳ͸ 
Genomes Project data (phase 1; http://www.internationalgenome.org/data/) to ͳ͹ 
determine consensus alleles by taking the most frequent allele of each of 20 target SNP ͳͺ 
sites. Some of SNP sites are not variable among 16 haplotypes, and consensus alleles of ͳͻ 
variable SNPs are indicated in Figure 1B together with 2 exon SNPs used to define ʹͲ 
haplotypes. In 1000 Genomes data, hap.10 is not present, and therefore excluded in this ʹͳ 
analysis.  ʹʹ ʹ͵ 
Haplotypes of publicly available cell lines ʹͶ 
 ͹
We assembled genotypes of 21 tagging SNPs, either from genome-wide association ͳ 
data5 or from specific TaqMan assays applied to DNA from blood, lymphoblasts, ʹ 
fibroblasts, induced pluripotent stem cells (iPSC) or derived neural progenitor cells. ͵ 
Those cell line data described in this study represent 59 individuals whose fibroblast Ͷ 
cell lines are available in public repositories and 7 human embryonic stem cell (hESC) ͷ 
lines from Genea Biocells Inc. (http://geneabiocells.com/). HTT CAG repeat length was ͸ 
also determined as described previously.20 Cell line genotype data and the HTT CAG ͹ 
repeat genotype coded as a bi-allelic system (expanded or normal) were combined for ͺ 
haplotype phasing in order to identify haplotype carrying expanded CAG or normal ͻ 
repeat. Genotype data for HD and control subjects that were used to define haplotypes14ͳͲ 
were also included to increase the accuracy of computational population phasing by the ͳͳ 
MaCH program.19 Familial relationships (S. Table 1) were further considered when the ͳʹ 
relationships between CAG repeats and haplotypes were ambiguous to determine the ͳ͵ 
phase of CAG repeats and haplotypes (e.g., control subjects).  ͳͶ ͳͷ 
Frequencies of haplotypes and haplogroups in control samples ͳ͸ 
Fully phased 1000 Genomes Project data (Phase 1; ͳ͹ 
http://www.internationalgenome.org/) were used to estimate population frequencies of ͳͺ 
HTT haplotypes defined in this study and haplogroups described by Kay et. al.11 Each ͳͻ 
chromosome was classified into haplotypes based on 21 SNPs, and further summarized ʹͲ 
for each population group (i.e., Europeans, Asians, Africans, and Ad Mixed ʹͳ 
Americans). The haplogroup of each chromosome was determined similarly based on ʹʹ 
63 SNPs, permitting direct delineation of correspondence between haplotype systems ʹ͵ 
on normal chromosomes.  ʹͶ 
 ͺ
ͳ 
Genotype imputation of HD samples  ʹ 
Genotypes on chromosome 4 were imputed for HD samples with European ancestry ͵ 
used in a recent onset-modifier genome-wide association (GWA) study (4082 Ͷ 
Europeans) 5 and control samples (1676 Europeans) 21 using the Michigan Imputation ͷ 
Server.22 Pre-phasing was performed by Eagle2 23 and imputation was performed by ͸ 
Minimac3 using 1000 Genomes Phase 1 as a reference panel (all populations).24 A set ͹ 
of SNPs used for haplotype and/or haplogroup analysis were then extracted from ͺ 
imputed data to determine relationships between haplotypes and haplogroups. ͻ ͳͲ 
Determination of the relationship between haplotypes and haplogroups ͳͳ 
Twenty-one genetic variations from our study14 and 63 tagging SNPs from Kay and ͳʹ 
colleagues11 were used to classify haplotypes of samples used in the HD modifier ͳ͵ 
GWA study.5 There were 10 shared SNPs between the two haplotype systems ͳͶ 
(rs2798296, GRCh37 chr4:g.3062165A>G; rs3856973, GRCh37 chr4:g.3080173G>A; ͳͷ 
rs2285086, GRCh37 chr4:g.3089259A>G; rs10015979, GRCh37 chr4:g.3109442A>G; ͳ͸ 
rs11731237, GRCh37 chr4:g.3151813C>T; rs363096, GRCh37 chr4:g.3180021T>C; ͳ͹ 
rs2298969, GRCh37 chr4:g.3186244A>G; rs363092, GRCh37 chr4:g.3196029A>C; ͳͺ 
rs916171, GRCh37 chr4:g.3216815C>G; and rs362272, GRCh37 chr4:g.3234980G>A) ͳͻ 
so genotypes for a total of 74 variants were extracted from the imputed data. Then the ʹͲ 
recoded bi-allelic HTT CAG repeat length genotype (expanded or normal) was added to ʹͳ 
the imputed genotype data, and haplotype phasing was performed for the 75 variant ʹʹ 
sites in the HD samples (4082 Europeans),5 control samples (1676 Europeans),21 and ʹ͵ 
1000 Genomes Phase 1 samples (379 Europeans, 181 Ad Mixed Americans, 246 ʹͶ 
 ͻ
Africans, 286 Asians)24 by the Beagle program.25 Subsequently, the CAG-expanded ͳ 
and normal chromosomes from each HD heterozygous subject (4078 Europeans) were ʹ 
named based on 1) our haplotype definitions, and 2) haplotype definitions used by Kay ͵ 
and colleagues11 in order to delineate the relationships between the two haplotype Ͷ 
systems. ͷ ͸ 
Description of SNPs, Website, and public access ͹ 
Detailed description of SNPs used in this study can be found in S. Table 2. In addition, ͺ 
description of SNPs, definition of haplotypes, and genotype data are available at ͻ 
chgr.partners.org/htt.haplotype.html. The genotype data set is also avalable at the ͳͲ 
European Variation Archive (http://www.ebi.ac.uk/eva/) (accession numer: ͳͳ 
PRJEB20817).  ͳʹ ͳ͵ ͳͶ 
 ͳͲ
RESULTS ͳ ʹ 
Common SNP-based haplotypes ͵ 
We previously defined the 8 most frequent haplotypes (hap.01 to hap.08) on HD Ͷ 
disease-causing chromosomes using 21 common genetic variants, including 20 SNPs ͷ 
and one 3 bp indel, genotyped in 699 unrelated HD subjects and 1,676 population ͸ 
controls of European ancestry.14,18 Approximate locations and alleles of DNA ͹ 
variations that were used for haplotype analysis are summarized in Figure 1A. Here, we ͺ 
extend the definitions in that dataset to the most frequent 10 HD and the 10 most ͻ 
frequent normal European HTT haplotypes. Four haplotypes were shared between the ͳͲ 
two groups, so the union created a single set of 16 different haplotypes. These were ͳͳ 
named based first upon decreasing frequency on CAG-expanded disease chromosomes ͳʹ 
in this initial HD dataset (hap.01 through hap.10) and then, after excluding the four ͳ͵ 
shared haplotypes (hap.08, hap.02, hap.03 and hap.01, in order of normal frequency), ͳͶ 
based upon decreasing frequency on normal chromosomes (hap.11 through hap.16); all ͳͷ 
other rare haplotypes were grouped as “hap.other”. A comparison of the potential ͳ͸ 
relationships between these 16 haplotypes was achieved by phylogeny analysis using a ͳ͹ 
neighbor-joining algorithm. The result is a dendrogram with two main branches ͳͺ 
containing different-sized sub-clusters (Figure 1A). For example, hap.01, the most ͳͻ 
common haplotype on the HD disease chromosomes forms a cluster with hap.05 and ʹͲ 
hap.10, whereas hap.08, the most common haplotype on normal chromosomes is a part ʹͳ 
of a cluster of haplotypes involving hap.04, hap.16, and hap.14. Divergence of related ʹʹ 
haplotypes could potentially be explained by a single marker allele change in some ʹ͵ 
cases (e.g., hap.01, hap.05, and hap.10; hap.11 and hap.12; hap.02 and hap.07; hap.04 ʹͶ 
 ͳͳ
and hap.16), by insertion/deletion of a simple repeat (e.g., hap.01 and hap.12), and by ͳ 
combinations of various genetic events including local recombination or gene ʹ 
conversion. The two main branches of the dendrogram suggest at least two different ͵ 
ancestral origins of de novo CAG expansion mutation. However, it is likely that the Ͷ 
haplotype diversity within the subclusters reflects the occurrence of many more de ͷ 
novo expansions rather than being the result of haplotype decay since we have ͸ 
previously demonstrated de novo CAG expansion on both hap.01 and hap.05.18͹ ͺ 
Haplotype-specific target SNP sites for allele-specific silencing ͻ 
Initial selection of SNPs for haplotyping was based on comparisons between HD ͳͲ 
subjects and normal control individuals, and therefore did not represent the ͳͳ 
combination of disease chromosomes and normal chromosomes in HD subjects.14ͳʹ 
Subsequently, we performed iterative heterozygosity analyses aiming at revealing a ͳ͵ 
minimal number of SNPs covering the maximum proportion of HD patients in allele-ͳͶ 
specific gene targeting therapies.18 Cumulatively, 10 exon SNPs and 10 intron SNPs ͳͷ 
covered 93.8% and 97.% of HD subjects, respectively, indicating that the vast majority ͳ͸ 
of HD subjects with Enropean ancestry carry at least one heterozygous SNP site among ͳ͹ 
20 nominated targetable locations.18 However, the heterozygosity analysis did not ͳͺ 
immediately show mutant alleles to target. Here, we determined consensus alleles of 20 ͳͻ 
targetable SNP sites on each of haplotypes based on 1000 Genomes Project data, and ʹͲ 
mapped variable alleles on eah haplotype. As summarized in Figure 1B, target SNP ʹͳ 
sites for each diplotype can be selected immediately by comparing two haplotypes ʹʹ 
(assuming one is mutant chromosome and the other is normal chromosome). For ʹ͵ 
example, if a HD individual carries mutant hap.01 and normal hap.08 chromosomes, ʹͶ 
 ͳʹ
there are 12 SNP sites that can be used to distinguish mutant allele from normal allele ͳ 
(Figure 1B).  ʹ ͵ 
Haplotypes of publicly available cell line resources Ͷ 
Results of mutant allele-specific gene silencing studies have produced promising ͷ 
results in animal models,10 encouraging the application of this approach to human HD. ͸ 
In this context, cell lines derived from HD subjects provide valuable tools to test the ͹ 
specificity and efficacy of allele-specific silencing reagents in pre-clinical experiments. ͺ 
Thus, we performed haplotype analysis using our haplotype system for HD cell lines ͻ 
readily available from various public repositories. Table 1 gives the HTT haplotypes for ͳͲ 
59 fibroblast lines available from the NIGMS Repository at the Coriell Institute ͳͳ 
(https://catalog.coriell.org/1/NIGMS) or the NINDS Human Cell and Data Repository ͳʹ 
at RUCDR Infinite Biologics (https://nindsgenetics.org/). These include 43 lines ͳ͵ 
representing individuals (from 26 families) with an expanded HTT repeat, whose allele ͳͶ 
lengths range from 38 to 180 CAGs. The remaining 16 lines from 10 families represent ͳͷ 
control individuals with CAG repeat lengths 33 or shorter. Where possible the phase of ͳ͸ 
the CAG repeat with respect to the HTT haplotype was confirmed from family ͳ͹ 
relationships (S. Table 1). In the remaining instances (unrelated subjects; noted by * on ͳͺ 
the sample ID in Table 1), the phase of the expanded repeat was assigned ͳͻ 
probabilistically using MaCH program (see methods) or the phase of distinguishable ʹͲ 
normal alleles was assigned arbitrarily for control individuals. As expected from HD ʹͳ 
population data, the most frequent haplotype on the disease and normal chromosomes ʹʹ 
in these families are hap.01 and hap.08, respectively, and this most common HD ʹ͵ 
diplotype, hap.01/hap.08, is present in multiple lines from independent families. ʹͶ 
 ͳ͵
However, many other HD haplotypes and diplotypes are also represented. Only 5 of the ͳ 
HD individuals are homozygous for the same haplotype, and 4 of these, two of which ʹ 
are also homozygous for an expanded CAG repeat, derive from the large Venezuela ͵ 
HD kindreds in which the disease segregates with hap.03 haplotype.  Ͷ 
 Induced pluripotent stem cell (iPSC) lines are already available to the research ͷ 
community from the above repositories or from the Cedars-Sinai iPSC Core ͸ 
(https://www.cedars-sinai.edu/Research/Research-Cores/Induced-Pluripotent-Stem-͹ 
Cell-Core-/) for 11 of the subjects with expanded repeat fibroblast lines and 5 of the ͺ 
normals, as noted in Table 1. In addition, we have performed haplotyping for 7 human ͻ 
embryonic stem cell (hESC) lines, with expanded CAG alleles ranging from 40 to 48 ͳͲ 
repeats, available from Genea Biocells, as shown in Table 2. The HD mutation in these ͳͳ 
lines resides either on hap.01 (4 independent lines) or hap.02 (3 lines from the same ͳʹ 
family).  ͳ͵ ͳͶ 
Haplogroup definition of HD chromosomes ͳͷ 
A different set of genetic markers (S. Table 2) has been used by others to define ͳ͸ 
haplogroups A, B and C, each of which represents a cluster of similar haplotypes.13,16,17ͳ͹ 
Recently, Kay et al. performed a more detailed analysis of the haplogroup system in ͳͺ 
738 European reference haplotypes from the 1000 Genomes Project and 2,364 ͳͻ 
haplotypes from HD patients and relatives in Canada and Europe to define individual ʹͲ 
subtypes within each haplogroup based upon 63 genetic variants across HTT.11 Across ʹͳ 
the Canadian and European HD subjects, selected subtypes from the A haplogroup ʹʹ 
accounted for 86% of all CAG-expanded chromosomes, but the remaining HD ʹ͵ 
 ͳͶ
chromosomes fell into haplogroup B or C subtypes or rarely, into none of the three ͳ 
major haplogroups (“Other”).  ʹ ͵ 
Comparison and integration of the two HTT haplotype systems  Ͷ 
Between the 21 markers used in our haplotype system and the 63 markers used in the ͷ 
recent subdividing of A, B, and C haplogroups, only 10 markers are overlapping (S. ͸ 
Table 2). In order to maximize the utility of both haplotype systems, we have directly ͹ 
compared them by examining the fully phased 1000 Genomes Project haplotype data ͺ 
(Phase 1, Release v3; http://www.internationalgenome.org/). To extend the analysis ͻ 
across all available populations rather than only Europeans, we analyzed a total of ͳͲ 
1,092 control individuals (2,184 normal chromosomes) consisting of Africans (ASW, ͳͳ 
LWK and YRI), Ad Mixed Americans (CLM, MXL, and PUR), East Asians (CHB, ͳʹ 
CHS, and JPT) and Europeans (CEU, FIN, GBR, IBS, and TSI). Each 1000 Genomes ͳ͵ 
chromosome was independently classified into our haplotypes using 21 variants sites ͳͶ 
and haplogroup subtypes using 63 variant sites. The hap.01-hap.16 designations ͳͷ 
encompassed almost 76% of European chromosomes and more than 60% of Ad Mixed ͳ͸ 
American and Asian chromosomes, but only 23% of African chromosomes, which ͳ͹ 
display far greater genetic complexity (S. Table 3). A similar pattern was evident using ͳͺ 
haplogroup subtypes which accounted for almost 67% of European chromosomes, ͳͻ 
about half of Ad Mixed American and Asian chromosomes and only about 7% of ʹͲ 
African chromosomes (S. Table 3). Subsequently, we delineated the relationships ʹͳ 
between the two haplotype systems by calculating the percentage of chromosomes with ʹʹ 
each haplotype defined in our system that distributed to each haplotype defined in the ʹ͵ 
haplogroup system (S. Table 4; Figure 2) and, vice versa (S. Table 5). For example, ʹͶ 
 ͳͷ
93.6% and 100% of chromosomes defined as bearing the related hap.01 or hap.05 ͳ 
haplotypes are classified as haplogroup subtype A1a (S. Table 4; Figure 2). Among ʹ 
only Europeans, the same correspondence is 100% for both haplotypes. The third ͵ 
related member of this haplotype subcluster from Figure 1, hap.10, was originally Ͷ 
defined from HD chromosomes but was not seen on any 1000 Genomes Project ͷ 
chromosomes and so is not reflected in the Tables. The haplotype most common on ͸ 
European normal chromosomes, hap.08, corresponds 95.1% of the time with the C1 ͹ 
subtype designation in the haplogroup system (S. Table 4). However for some other ͺ 
haplotypes, the correspondence is not so direct, as some hap.02 chromosomes (25.6%) ͻ 
are classified as haplogroup subtype A2a while others (61.0%) are classified as A2b. ͳͲ 
Similarly, hap.06 also divides between these two related A2 subtypes, but is primarily ͳͳ 
assigned to the “Other” class, not being classified as haplogroup A, B or C. ͳʹ 
Interestingly, haplotypes hap.04, hap.07 and hap.09, which were named by decreasing ͳ͵ 
order of their frequency on HD disease chromosomes in our original study all ͳͶ 
correspond to the “Other” class of haplogroups except 12.5% of the hap.04 group, ͳͷ 
which are designated as C4b. ͳ͸ 
 Considering the reverse comparison of chromosomes named by the haplogroup ͳ͹ 
system to our haplotypes (S. Table 5), the correspondence is similar to the above, with ͳͺ 
the A1, A2 and A3 designations, which are the most common on European HD ͳͻ 
chromosomes, corresponding largely to hap.01+hap.05, hap.02+hap.06 and hap.03, ʹͲ 
respectively, encompassing most of the haplotypes seen frequently on European HD ʹͳ 
chromosomes. Those haplogroup subtypes rarely seen on HD chromosomes, such as ʹʹ 
A4a, A4b, A5a, A5b, B1a, C2, C4 and C6 correspond largely with haplotypes seen on ʹ͵ 
the normal chromosomes in our HD dataset (hap.12, hap.11, hap.12, hap.15, hap.13, ʹͶ 
 ͳ͸
hap.14, hap.16, and hap.14, respectively), or in the cases of B1b, B2, C3, C5, C7 and ͳ 
C8, among the mixed hap.other group of less frequent normal haplotypes.  ʹ 
 Overall, these comparisons indicate that the haplotypes most frequently ͵ 
associated with HD disease chromosomes (i.e., hap.01, hap.02, and hap.03) correspond Ͷ 
in general with haplogroup subtypes A1, A2, and A3. However, there is the potential ͷ 
for additional resolution in both systems, as illustrated by the fact that the subtypes of ͸ 
A2 (A2a and A2b) subdivide the hap.02 chromosomes, but each subtype (A2a and ͹ 
A2b) is also classified into either hap.02 or hap.06. Similarly, the lack of strong ͺ 
correspondence with haplogroup subtypes of some of the rarer haplotypes identified on ͻ 
HD chromosomes in our studies suggests yet greater diversity among disease ͳͲ 
chromosomes, and predicts that additional genetic variants can further subdivide the ͳͳ 
defined haplotypes and haplogroups, particularly in non-European populations. ͳʹ ͳ͵ 
HTT haplotype frequencies on CAG-expanded and normal chromosomesͳͶ 
The comparisons in S. Tables 4 and 5 relied on fully phased control chromosomes to ͳͷ 
define haplotype/haplogroup relationships in samples with various ancestries. To ͳ͸ 
estimate the frequency of these groupings on HD chromosomes of European ancestry, ͳ͹ 
we examined the imputed genotypes of 4,078 heterozygous HD subjects recently ͳͺ 
studied in a GWA study of HD modifiers.5 We extracted a unionset of 74 SNPs ͳͻ 
(representing 21 SNPs used to define our HTT haplotypes and the 53 non-overlapping ʹͲ 
variant sites used by Kay et. al.), and performed probabilistic phasing of the marker ʹͳ 
alleles using the Beagle program.25 Each of 74-SNP haplotypes (either expanded CAG ʹʹ 
or normal CAG chromosome) was assigned to both a haplotype and a haplogroup ʹ͵ 
subtype, generating a data set that permited assessment of the frequency of each ʹͶ 
 ͳ͹
haplotype/haplogroup subtype combination. When focusing on our haplotypes defined ͳ 
in this study (Figure 1), frequencies of haplotypes of the expanded and normal ʹ 
chromosomes based on a large collection of HD subjects with European ancestry ͵ 
revealed that HD expansion mutation sits on diverse haplotypes that are also present in Ͷ 
normal chromosomes (Figure 3). In addition, comparisons of haplotype frequencies ͷ 
revealed overrepresented and underrepresented haplotypes in HD. For example, hap.01 ͸ 
and hap.08 are enriched in disease and normal chromosomes, respectively (Figure 3). ͹ 
Frequency data predicted that the most common diplotype in heterozygous HD subjects ͺ 
would be expanded CAG repeat on hap.01 and normal CAG repeat on hap.08. When ͻ 
comparing our haplotypes to haplogroup, overall, 78% and 71% of European HD and ͳͲ 
normal chromosomes, respectively, were assignable to discrete ‘super’-haplotype ͳͳ 
backbones that combined discrete haplotypes and haplogroup subtypes, excluding the ͳʹ 
uncertain hap.other and haplogroup ‘Other” catch-all categories (Table 3). As expected, ͳ͵ 
the most frequent HD chromosome backbone was hap.01/A1a and comprised over 38% ͳͶ 
of European HD chromosomes from the GWA study. Similarly, the most frequent ͳͷ 
control backbone hap.08/C1 accounted for about 25% of normal chromosomes. ͳ͸ 
Examination of diplotypes of the 4,078 European HD individuals revealed that 56% ͳ͹ 
possessed HD and normal chromosomes that could both be assigned to a fully-defined ͳͺ 
haplotype/haplogroup backbone, without the uncertainty of the hap.other and ͳͻ 
haplogroup ‘Other’ categories (Table 4). Notably, less than 5% of these HD subjects ʹͲ 
had fully-defined chromosomal backbones that were identical on disease and normal ʹͳ 
chromosomes, being homozygous for all tagging markers. If all 4,078 heterozygous ʹʹ 
HD subjects were analyzed, 4.9% of them carry identical alleles for 74 SNPs, ʹ͵ 
suggesting that the majority of HD subjects of European descents are eligible for allele-ʹͶ 
 ͳͺ
specific gene targeting strategies. Our previous full sequence analysis of HD hap.01 ͳ 
chromosomes suggests that many of the individuals with the same haplotype backbone ʹ 
on the normal and disease chromosomes could harbour heterozygous variants not ͵ 
considered in the current haplotypes/haplogroups,18 further implying an additional Ͷ 
likelihood of allele discrimination. ͷ ͸ 
DISCUSSION ͹ 
Huntingtin (HTT) shows evolutionarily conserved structural characteristics, and ͺ 
deficiency or hypomorphism of huntingtin are associated with pleiotropic effects ͻ 
involving a number of critical biological processes,26 suggesting that HTT silencing ͳͲ 
approaches to treat HD may need to be specific to the mutant allele. Allele-specific ͳͳ 
silencing of HTT can be achieved either by directly targeting the CAG repeats or, ͳʹ 
alternatively, by targeting polymorphisms in linkage disequilibrium (LD) with the ͳ͵ 
CAG expansion.8,10 Because the HD mutation can occur across a wide range of ͳͶ 
pathogenic sizes, and CAG repeats are found in many other genes, directly targeting the ͳͷ 
CAG expansion could result in variable levels of allele selectivity and off-target effects. ͳ͸ 
Previous studies have demonstrated the feasibility of silencing the expression of the ͳ͹ 
expanded allele by targeting a variation on the expanded chromosome.10,27-29 Recently, ͳͺ 
SNP heterozygosity analysis has revealed that the disease chromosome can be ͳͻ 
distinguished from the normal chromosome in most HD subjects of European ʹͲ 
ancestry.11,16,18,28,30 Theraeputic strategy leveraging a SNP-targeting approach is ʹͳ 
therefore possible (Figure 1B), but would require knowledge about presence of target ʹʹ 
SNP site, haplotype phasing, and preferably additional exon SNP sites for outcome ʹ͵ 
measurements (i.e., levels of mutant HTT) for a given HD individual. Still, analytical ʹͶ 
 ͳͻ
pipelines to identify variant alleles on the CAG-expanded chromosome of an HD ͳ 
individual are yet to be developed because simple genotyping assays do not ʹ 
differentiate allelic phase unless family members are also analyzed. This limitation can ͵ 
be overcome by computational haplotype phasing approaches, because haplotype Ͷ 
phasing with a large collection of HD data allows relatively accurate inference of the ͷ 
disease and normal chromosome. Results described here on haplotype phasing of large ͸ 
populus of HD individuals, can help populate attributes on HD patient database, and ͹ 
inform where patient groups enriched for targeting SNP can be sought. Subsequent ͺ 
sequence analysis of representative common HD haplotypes and pair-wise comparisons ͻ 
then provide a comprehensive list of targetable sites for each diplotype. In addition, ͳͲ 
development of allele-specific HTT quantification assays to assess the efficacy and ͳͳ 
allele specificity of silencing reagents require knowledge of variations and their ͳʹ 
relationships to the expanded chromosomes. Therefore, haplotypes of expanded ͳ͵ 
chromosomes, individual-level diplotype data, and our analytical pipelines provide ͳͶ 
guidance for identifying targets for mutant allele-specific HTT lowering strategies and a ͳͷ 
route to developing allele-specific readouts to assess specificity of silencing reagents. ͳ͸ 
In addition, genome-wide genotyping assays for HD subjects in a large observational ͳ͹ 
study is on going (i.e., ENROLL-HD), and our pipelines can efficiently identify each ͳͺ 
individual's expanded and normal chromosomes. Such individual level diplotype data ͳͻ 
will be critically important in stratifying subjects to identify optimal study populatons ʹͲ 
in clinical trials.  ʹͳ 
 In summary, we performed individual level haplotype analyses on a large ʹʹ 
cohort of HD subjects to evaluate the power of haplotype-based genetics in stratifying ʹ͵ 
HD subjects. Our haplotypes based on a relatively small number of SNPs were able to ʹͶ 
 ʹͲ
distinguish mutant chromosomes from their normal counterparts, and confirmed that ͳ 
the majority of HD subjects carry two different haplotypes, further supporting the ʹ 
conclusion from population-based SNP analysis that most HD individuals could be ͵ 
eligible for allele-specific gene silencing18 and demonstrating the efficiency of Ͷ 
haplotype-based approaches. By providing the HD haplotypes of commonly-used ͷ 
publicly available cell lines and a haplotype conversion tables for the comparable ͸ 
haplogroup classification strategy, we hope to promote and facilitate the use of these ͹ 
resources to accelerate pre-clinical allele-specific gene silencing studies and a true ͺ 
precision medicine approach to HD.  ͻ ͳͲ 
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Figure Legends ͳ ʹ 
Figure 1. Definitions and sequence relationships of HTT haplotypes.  ͵ 
(A) Twenty-one SNPs, one 3bp indel (rs149109767, alleles R-reference & D-deletion) Ͷ 
and the CAG repeat polymorphism are shown at their genomic locations relative to that ͷ 
of the HTT RefSeq transcript (NM_002111). Genotype at each marker on each of 16 ͸ 
HTT haplotypes, defined in the text, is shown above the marker. Haplotypes are ͹ 
ordered based upon a neighbor-joining method (p-distance model) in a dendrogram ͺ 
with two main branches, each with different sizes of sub-clusters. Alleles in red ͻ 
represent differences from hap.01, the most frequent haplotype on CAG-expanded HD ͳͲ 
chromosomes. ͳͳ 
(B) Consensus alleles of 10 exon SNPs and 10 intron SNPs that showed the biggest ͳʹ 
cumulative heterozygosity were determined for each haplotype based on 1000 ͳ͵ 
Genomes Project data. A consensus allele for a given SNP site represents the most ͳͶ 
frequent allele among a collection of chromosomes with same haplotpye. Since hap.10 ͳͷ 
is not present in 1000 Genomes data (Phase 1), hap.10 was excluded in this analysis. ͳ͸ 
Subsequently, alleles of SNPs that show variable alleles in 15 haplotypes and alleles of ͳ͹ 
two exon SNPs that were used to define the haplotypes are indicated. SNPs in orange ͳͺ 
and black font colors represent SNPs on exons and introns of RefSeq NM_002111, ͳͻ 
respectively.  ʹͲ ʹͳ 
Figure 2. Correspondences of haplotypes and haplogroups.  ʹʹ 
Based on S. Table 4, correspondences of haplotypes to haplogroups were summarized. ʹ͵ 
"hap.other" and "Other" were excluded to focus on distinct haplotypes. Thickness of an ʹͶ 
 ʹ͹
arrow represents relative proportion of a specific haplotype-haplogroup correspondence ͳ 
for a given haplotype. For example, most of hap.02 is classified as haplogroup A2b, ʹ 
and a small portion of hap.02 is classified as haplogroup A2a. Actual haplotype-͵ 
haplogroup correspondence data can be found in S. Table 4. Ͷ ͷ 
FIgure 3. Frequencies of haplotypes in HD disease and normal chromosomes.  ͸ 
HD subjects carrying one expanded and one normal chromosome were included in this ͹ 
analysis to estimate overall frequencies of haplotypes. From haplotypes ͺ 
probabilisitcally determined based on union set of 74 SNPs, we used our haplotype ͻ 
definitions to calssify each chromosome. Subsequently, frequencies of our haplotypes ͳͲ 
in HD disease chromosomes (A) and normal chromosomes in HD subjects (B) were ͳͳ 
calcuated and summarized. ͳʹ ͳ͵ ͳͶ ͳͷ 
 ʹͺ
Table 1. HTT haplotypes of publicly available cell resouces. ͳ 
Sample ID Gender 
Chromosome 1 Chromosome 2 
CAG Haplotype CAG Haplotype 
GM02077 Female 44 hap.01 17 hap.03 
GM02079 Female 44 hap.01 21 hap.02 
GM02147 Male 43 hap.06 15 hap.08 
GM02149 Female 18 hap.08 18 hap.13 
GM02151 Female 45 hap.06 18 hap.08 
GM06274 Female 43 hap.06 16 hap.11 
GM02153 Female 32 hap.other 16 hap.14 
GM02155 Female 17 hap.12 16 hap.14 
GM02157 Female 17 hap.12 16 hap.14 
GM02159 Female 32 hap.other 17 hap.12 
GM02161 Male 17 hap.12 16 hap.14 
GM02163 Male 47 hap.other 32 hap.other 
GM02165 Male 44 hap.01 33 hap.other 
GM02177 Male 44 hap.01 18 hap.08 
GM02183 Female 33 hap.other 18 hap.08 
GM03621 Female 60 hap.01 18 hap.other 
GM02171 Female 17 hap.14 17 hap.08 
GM02173 Female 44 hap.01 17 hap.08 
GM02175 Male 20 hap.other 17 hap.14 
GM00305* Female 43 hap.other 17 hap.12 
GM01061* Male 44 hap.01 18 hap.other 
 ʹͻ
GM01085* Male 44 hap.other 21 hap.other 
GM03814* Female 28 hap.01 22 hap.02 
GM03864 Female 45 hap.01 15 hap.15 
GM03866 Female 43 hap.01 21 hap.02 
GM03868 Female 47 hap.01 17 hap.11 
GM03872 Male 21 hap.02 15 hap.15 
GM04188 Female 16 hap.14 15 hap.08 
GM04200 Male 45 hap.07 16 hap.14 
GM04281 Female 78 hap.03 17 hap.11 
GM04689 Female 45 hap.03 16 hap.other 
GM04717 Female 42 hap.03 29 hap.02 
GM04773 Female 38 hap.03 15 hap.08 
GM04777 Male 44 hap.03 18 hap.03 
GM04805 Female 29 hap.other 15 hap.08 
GM04807 Male 50 hap.03 38 hap.03 
GM04887 Female 45 hap.03 21 hap.02 
GM04287 Male 51 hap.03 17 hap.03 
GM04687 Female 50 hap.03 15 hap.15 
GM04723 Female 69 hap.03 15 hap.08 
GM04729* Female 17 hap.08 17 hap.11 
GM04797 Female 17 hap.08 15 hap.15 
GM04849 Female 51 hap.03 45 hap.03 
GM08330* Male 17 hap.08 17 hap.other 
GM21756* Female 69 hap.03 15 hap.08 
 ͵Ͳ
GM21757* Male 63 hap.03 16 hap.12 
GM01168* Male 48 hap.other 25 hap.11 
GM01169* Male 44 hap.01 17 hap.08 
GM01187* Male 46 hap.01 18 hap.12 
GM05539* Male 96 hap.03 22 hap.02 
ND31551* Male 39 hap.08 18 hap.13 
ND33947* Female 40 hap.01 18 hap.08 
ND30013* Male 43 hap.09 17 hap.other 
ND30259* Female 38 hap.06 21 hap.other 
ND30626 Male 41 hap.02 17 hap.11 
ND31038 Female 44 hap.02 19 hap.02 
ND29970* Male 40 hap.04 17 hap.other 
ND33392* Female 56 hap.07 17 hap.08 
GM09197* Male 180 hap.01 18 hap.08 ͳ 
Computational haplotype phasing analysis was performed using 21 SNPs and biallele ʹ 
coding genotype of HTT CAG repeats as described in the method section. ͵ 
Subsequently, phased alleles of CAG repeat genotype and family relationships (refer to Ͷ 
S. Table 1) were considered to determine and confirm the phase of CAG repeat size ͷ 
and HTT haplotype. In some cases, genotypes and haplotypes of relatives were not ͸ 
available, or family relationshp was not informative in determining the phase. In such ͹ 
cases, only probalistic population phasing results are shown (samples marked by *). ͺ 
* population probabilistic phasing for HD; arbitrary phasing for controls.  ͻ ͳͲ 
 ͵ͳ
Table 2. Sample information and phased haplotypes of hESC from of Genea ͳ 
Biocells.ʹ 





CAG haplotype CAG haplotype 
GENEA017 Male  40 hap.01 12 hap.other 
GENEA018 Female  46 hap.01 17 hap.other 
GENEA020 Female  48 hap.01 17 hap.03 
GENEA046 Female  45 hap.01 23 hap.02 
GENEA089 Female 
Sib to 090 
& 091 
42 hap.02 18 hap.08 
GENEA090 Female 
Sib to 089 
& 091 
46 hap.02 19 hap.02 
GENEA091 Female 
Sib to 089 
& 090 
41 hap.02 19 hap.02 
͵ 
Computational haplotype phasing analysis was performed to determine haplotypes and Ͷ 
corresponding CAG repeat sizes of embronic stem cell lines from Genea Biocells. Each ͷ 
phased disease (CAG-expanded) or normal chromosome consists of two components: ͸ 
CAG and HTT. This collection include related individuals (siblings) as shown in the ͹ 
Sibship column. ͺ ͻ ͳͲ ͳͳ ͳʹ 
 ͵ʹ
Table 3. Frequency of combined haplotype/haplogroup system backbones on ͳ 
CAG- expanded and normal chromosomes in European HD subjects. ʹ ͵ 
'Super'-haplotype of CAG-expanded chromosomes 
Haplotype Haplogroup 
# HD disease 
chromosomes Percent 
hap.01 A1a 1556 38.16% 
hap.02 A2b 553 13.56% 
hap.03 A3a 323 7.92% 
hap.02 A2a 291 7.14% 
hap.05 A1a 164 4.02% 
hap.08 C1 136 3.33% 
hap.06 A2b 107 2.62% 
hap.06 A2a 60 1.47% 
hap.11 A4b 3 0.07% 
hap.12 A5a 3 0.07% 
hap.15 A5b 2 0.05% 
hap.12 A1a 1 0.02% 
Sum   78.45% 
Haplotype "hap.other" or haplogroup "Other" categories of CAG-expanded 
chromosomes 
Haplotype Haplogroup 
# HD disease 
chromosomes Percent 
 ͵͵
hap.other Other 380 9.32% 
hap.04 Other 134 3.29% 
hap.07 Other 134 3.29% 
hap.12 Other 51 1.25% 
hap.02 Other 33 0.81% 
hap.06 Other 30 0.74% 
hap.other B2 22 0.54% 
hap.09 Other 18 0.44% 
hap.11 Other 17 0.42% 
hap.14 Other 14 0.34% 
hap.01 Other 13 0.32% 
hap.16 Other 10 0.25% 
hap.other C5 7 0.17% 
hap.05 Other 4 0.10% 
hap.03 Other 3 0.07% 
hap.other B1b 3 0.07% 
hap.other A2b 2 0.05% 
hap.other A5a 2 0.05% 
hap.08 Other 1 0.02% 
hap.other A1a 1 0.02% 
Sum   21.55% 
'Super'-haplotype of normal chromosomes
Haplotype Haplogroup # Normal chromosomes Percent  
 ͵Ͷ
hap.08 C1 1034 25.36% 
hap.03 A3a 479 11.75% 
hap.02 A2b 242 5.93% 
hap.11 A4b 197 4.83% 
hap.02 A2a 153 3.75% 
hap.13 B1a 141 3.46% 
hap.01 A1a 82 2.01% 
hap.12 A5a 81 1.99% 
hap.12 A4a 76 1.86% 
hap.15 A5b 71 1.74% 
hap.06 A2a 63 1.54% 
hap.14 C6 61 1.50% 
hap.06 A2b 53 1.30% 
hap.16 C4b 51 1.25% 
hap.16 C4a 47 1.15% 
hap.05 A1a 42 1.03% 
hap.14 C2 26 0.64% 
hap.10 A1a 1 0.02% 
hap.12 A1a 1 0.02% 
Sum   71.14% 
Haplotype "hap.other" or haplogroup "Other" categories of normal 
chromosomes 
Haplotype Haplogroup # Normal chromosomes Percent  
 ͵ͷ
hap.other Other 559 13.71% 
hap.12 Other 187 4.59% 
hap.14 Other 96 2.35% 
hap.other B1b 73 1.79% 
hap.07 Other 54 1.32% 
hap.11 Other 47 1.15% 
hap.other C8 36 0.88% 
hap.03 Other 21 0.51% 
hap.06 Other 16 0.39% 
hap.other C5 14 0.34% 
hap.16 Other 11 0.27% 
hap.04 Other 10 0.25% 
hap.other C7 10 0.25% 
hap.02 Other 9 0.22% 
hap.01 Other 8 0.20% 
hap.other C1 6 0.15% 
hap.08 Other 4 0.10% 
hap.13 Other 3 0.07% 
hap.other B1a 3 0.07% 
hap.15 Other 2 0.05% 
hap.other A5a 2 0.05% 
hap.other B2 2 0.05% 
hap.other A2a 1 0.02% 
hap.other A4b 1 0.02% 
 ͵͸
hap.other A5b 1 0.02% 
Sum   28.84% ͳ 
Phased haplotypes of subjects (4078 heterozygous HD) were grouped into HD disease ʹ 
chromosomes and normal chromosomes. Subsequently, the frequency of each ͵ 
combined haplotype/haplogroup (i.e., 'super'-haplotype) was calculated for HD disease Ͷ 
and normal chromosomes. Frequency and corresponding percentage value of each ͷ 
'super'-haplotype were based on 1) haplotypes not involving "hap.other" or "Other" and ͸ 
2) haplotypes involving "hap.other" or "Other".  ͹ ͺ 
 ͵͹
Table 4. Fully-defined diplotypes in HD subjects with European ancestry. ͳ ʹ 
HD  Normal  # Subjects % of 4078 subjects 
hap.01 A1a hap.08 C1 350 8.58% 
hap.01 A1a hap.03 A3a 179 4.39% 
hap.02 A2b hap.08 C1 133 3.26% 
hap.01 A1a hap.02 A2b 121 2.97% 
hap.03 A3a hap.08 C1 114 2.80% 
hap.02 A2b hap.03 A3a 79 1.94% 
hap.02 A2a hap.08 C1 75 1.84% 
hap.01 A1a hap.11 A4b 70 1.72% 
hap.01 A1a hap.01 A1a 69 1.69% 
hap.01 A1a hap.02 A2a 69 1.69% 
hap.01 A1a hap.13 B1a 49 1.20% 
hap.08 C1 hap.08 C1 47 1.15% 
hap.02 A2a hap.03 A3a 40 0.98% 
hap.03 A3a hap.03 A3a 40 0.98% 
hap.05 A1a hap.08 C1 38 0.93% 
hap.01 A1a hap.05 A1a 34 0.83% 
hap.06 A2b hap.08 C1 34 0.83% 
hap.01 A1a hap.12 A4a 33 0.81% 
hap.02 A2b hap.02 A2b 29 0.71% 
hap.01 A1a hap.15 A5b 28 0.69% 
hap.02 A2b hap.11 A4b 28 0.69% 
 ͵ͺ
hap.01 A1a hap.12 A5a 27 0.66% 
hap.01 A1a hap.06 A2b 24 0.59% 
hap.02 A2b hap.02 A2a 24 0.59% 
hap.01 A1a hap.06 A2a 23 0.56% 
hap.01 A1a hap.14 C6 23 0.56% 
hap.02 A2b hap.13 B1a 19 0.47% 
hap.03 A3a hap.11 A4b 18 0.44% 
hap.03 A3a hap.13 B1a 17 0.42% 
hap.06 A2b hap.03 A3a 17 0.42% 
hap.01 A1a hap.16 C4a 16 0.39% 
hap.05 A1a hap.03 A3a 16 0.39% 
hap.06 A2a hap.03 A3a 16 0.39% 
hap.01 A1a hap.16 C4b 15 0.37% 
hap.02 A2a hap.02 A2b 15 0.37% 
hap.02 A2b hap.16 C4a 14 0.34% 
hap.02 A2b hap.14 C6 13 0.32% 
hap.06 A2a hap.08 C1 13 0.32% 
hap.02 A2a hap.11 A4b 12 0.29% 
hap.02 A2b hap.12 A5a 12 0.29% 
hap.03 A3a hap.12 A4a 11 0.27% 
hap.05 A1a hap.02 A2a 11 0.27% 
hap.02 A2a hap.02 A2a 10 0.25% 
hap.02 A2b hap.06 A2a 10 0.25% 
hap.02 A2b hap.06 A2b 10 0.25% 
 ͵ͻ
hap.05 A1a hap.02 A2b 10 0.25% 
hap.05 A1a hap.11 A4b 10 0.25% 
hap.06 A2b hap.02 A2b 10 0.25% 
hap.02 A2b hap.12 A4a 9 0.22% 
hap.08 C1 hap.11 A4b 9 0.22% 
hap.08 C1 hap.13 B1a 9 0.22% 
hap.02 A2b hap.15 A5b 8 0.20% 
hap.03 A3a hap.16 C4b 8 0.20% 
hap.02 A2a hap.06 A2a 7 0.17% 
hap.02 A2a hap.13 B1a 7 0.17% 
hap.03 A3a hap.12 A5a 7 0.17% 
hap.05 A1a hap.15 A5b 7 0.17% 
hap.08 C1 hap.12 A5a 7 0.17% 
hap.05 A1a hap.12 A4a 6 0.15% 
hap.05 A1a hap.13 B1a 6 0.15% 
hap.06 A2b hap.02 A2a 6 0.15% 
hap.01 A1a hap.14 C2 5 0.12% 
hap.02 A2a hap.16 C4a 5 0.12% 
hap.05 A1a hap.12 A5a 5 0.12% 
hap.08 C1 hap.16 C4b 5 0.12% 
hap.02 A2a hap.12 A4a 4 0.10% 
hap.02 A2a hap.15 A5b 4 0.10% 
hap.02 A2b hap.16 C4b 4 0.10% 
hap.03 A3a hap.14 C6 4 0.10% 
 ͶͲ
hap.03 A3a hap.15 A5b 4 0.10% 
hap.06 A2a hap.11 A4b 4 0.10% 
hap.08 C1 hap.15 A5b 4 0.10% 
hap.02 A2a hap.14 C2 3 0.07% 
hap.02 A2a hap.16 C4b 3 0.07% 
hap.02 A2b hap.05 A1a 3 0.07% 
hap.03 A3a hap.06 A2a 3 0.07% 
hap.03 A3a hap.14 C2 3 0.07% 
hap.05 A1a hap.14 C6 3 0.07% 
hap.05 A1a hap.16 C4b 3 0.07% 
hap.06 A2a hap.02 A2b 3 0.07% 
hap.06 A2b hap.11 A4b 3 0.07% 
hap.08 C1 hap.14 C2 3 0.07% 
hap.08 C1 hap.14 C6 3 0.07% 
hap.02 A2a hap.06 A2b 2 0.05% 
hap.02 A2a hap.12 A5a 2 0.05% 
hap.02 A2a hap.14 C6 2 0.05% 
hap.02 A2b hap.14 C2 2 0.05% 
hap.03 A3a hap.16 C4a 2 0.05% 
hap.05 A1a hap.06 A2b 2 0.05% 
hap.05 A1a hap.14 C2 2 0.05% 
hap.06 A2a hap.13 B1a 2 0.05% 
hap.06 A2a hap.16 C4b 2 0.05% 
hap.06 A2b hap.12 A4a 2 0.05% 
 Ͷͳ
hap.06 A2b hap.16 C4b 2 0.05% 
hap.08 C1 hap.16 C4a 2 0.05% 
hap.01 A1a hap.12 A1a 1 0.02% 
hap.03 A3a hap.02 A2a 1 0.02% 
hap.05 A1a hap.16 C4a 1 0.02% 
hap.06 A2a hap.06 A2a 1 0.02% 
hap.06 A2a hap.12 A5a 1 0.02% 
hap.06 A2b hap.06 A2a 1 0.02% 
hap.06 A2b hap.06 A2b 1 0.02% 
hap.06 A2b hap.12 A5a 1 0.02% 
hap.06 A2b hap.13 B1a 1 0.02% 
hap.06 A2b hap.15 A5b 1 0.02% 
hap.06 A2b hap.16 C4a 1 0.02% 
hap.08 C1 hap.12 A4a 1 0.02% 
hap.12 A5a hap.11 A4b 1 0.02% 
hap.12 A5a hap.13 B1a 1 0.02% 
hap.15 A5b hap.13 B1a 1 0.02% 
Total    2291 56.18% 
Total homozygous diplotype 197 4.83% ͳ 
To determine the proportion of HD subjects eligible for allele-specific gene targeting ʹ 
approaches, diplotype of each HD subject (i.e., HD disease chromosome and normal ͵ 
chromosome in a given HD subject) in our data was constructed based on 'super'-Ͷ 
haplotype system. Subsequently, the frequency of each unique diplotype was calcuated.  ͷ 
 Ͷʹ
Diplotypes in bold and italic represent HD subjects who carry the same haplotypes for ͳ 
disease and normal chrommosomes.  ʹ ͵ 
 Ͷ͵
Supplementary Tables ͳ 
S. Table 1. Familial relationships and other IDs of publicly available cell resouces ʹ 
S. Table 2. Description of SNPs used in this study.͵ 
S. Table 3. HTT haplotypes and haplogroup subtypes in the 1000 Genomes Project Ͷ 
Data. ͷ 
S. Table 4. Distribution of HTT haplogroup subtypes relative to HTT haplotypes. ͸ 









































































































































































































A A G G A G T T T G T T A C C A T D G C G
T A G G A A T T T G C C A C C A T R G C A
A A G G A G T T T G T T A C C A T R G C G
T A G G A A T T T G C C A C C A T R A T A
A A A G A A T T T G C T G C C A T R G C G
T A G G A G T T T G T T A C C A T D G C G
A G A A G A G T G A C C G A G G C R A T A
A G A G A G T T T G T T A C C A T R G C G
A A G G A G T C T G T T A C C A T D G C G
A A G G A G T T T G C T A C C A T R G C G
T A G G A A T T T G C C A C C A T R G C G
T A G A G A G C T G C C G A G G C R G C G
A A G G A G T T T G T T A C C A T R G C A
A A A A G A G T T A C C G A G G C R G C G
A A G G A A T T T G C C A C C A T R G C G





































































































































C C T T T T G D G G T T T C A C
C C T T T T G D G G T T T C G C
C C T T T T G R G G T T C C G C
C C T T T T G R G G T T C C G C
C C T T T T G R G G T T C C G C
T C C T T T G R A G T T C C G C
C C C T T T G R G G T C C C G T
C C C T T T G R G G T T C C G T
C C C T T T G R G G T T C C G T
C C C G T T G R G A C C C T G C
C C C G T T G R G G T T C C G C
C C C G C T G R G G T C C C G C
C C C G C T G R G G T C C C G C
C C C G C G T R G A C C C T G C
C T C G C T G R G G T T C C G C
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